公开(公告)号：US20240360216A1

公开(公告)日：2024-10-31

申请号：US18688387

申请日：2021-09-14

Applicant: NOVOPROTEIN SCIENTIFIC INC. ,  NOVOPROTEIN SCIENTIFIC (SHANGHAI) INC.

Inventor： Huaxing ZHU ,  Zuowei SONG ,  Debin LI ,  Futao YU ,  Zhaofeng QIN ,  Jixuan FANG ,  Mi WANG

IPC: C07K16/28 ,  A61K47/68 ,  A61P35/00 ,  G01N33/68

CPC classification number: C07K16/2809 ,  A61K47/6849 ,  A61P35/00 ,  G01N33/6854 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/92 ,  G01N2333/7051

Abstract: Provided is a novel anti-CD3 humanized antibody. The anti-CD3 humanized antibody can specifically bind to human and monkey CD3 proteins, and said antibody has good biological activity.

公开(公告)号：US12128102B2

公开(公告)日：2024-10-29

申请号：US18357013

申请日：2023-07-21

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Patrick Baeuerle ,  Robert B. DuBridge ,  Holger Wesche ,  Luke Evnin ,  Jeanmarie Guenot ,  Anand Panchal ,  Maia Vinogradova

IPC: G01N31/00 ,  A61K39/395 ,  A61P35/00 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  C07K16/46 ,  G01N33/53 ,  A61K39/00

CPC classification number: A61K39/39558 ,  A61P35/00 ,  C07K16/18 ,  C07K16/28 ,  C07K16/2809 ,  C07K16/2827 ,  C07K16/2863 ,  C07K16/30 ,  C07K16/468 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2317/62 ,  C07K2317/622 ,  C07K2317/94 ,  C07K2319/00 ,  C07K2319/50

Abstract: The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment.

公开(公告)号：US20240352139A1

公开(公告)日：2024-10-24

申请号：US18036144

申请日：2021-11-11

Applicant: BEIJING IMMUNOAH PHARMATECH CO., LTD.

Inventor： Xin GAO ,  Niliang QIAN ,  Xiujie PAN ,  Guili XU ,  Yujie LIU ,  Hongjie LI ,  Cuima YANG ,  Qinzhi XU ,  Xiaoqian DOU ,  Yunhui LIU ,  Zhenjun YU ,  Guijun BAI

IPC: C07K16/28 ,  A61P35/00 ,  C07K16/30

CPC classification number: C07K16/2878 ,  A61P35/00 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/2827 ,  C07K16/2863 ,  C07K16/2866 ,  C07K16/30 ,  C07K16/3007 ,  C07K16/3069 ,  C07K16/3084 ,  C07K16/3092 ,  C07K2317/21 ,  C07K2317/31

Abstract: The present application provides a fusion protein, containing: an anti-CD137 antibody capable of specifically binding to a CD137 molecule or an antigen binding fragment thereof; an anti-CD3 antibody capable of specifically binding to a CD3 molecule or an antigen binding fragment thereof; and a first peptide linker and a second peptide linker. The present application also provides a nucleic acid encoding the fusion protein, an expression vector containing the nucleic acid, a host cell containing the nucleic acid or the expression vector, a method for preparing the fusion protein, a pharmaceutical composition containing the fusion protein, and a use of the fusion protein.

公开(公告)号：USRE50178E1

公开(公告)日：2024-10-22

申请号：US17464970

申请日：2021-09-02

Applicant: UCB Biopharma SRL

Inventor： John Robert Adair ,  Diljeet Singh Athwal ,  John Spencer Emtage

IPC: C07K16/00 ,  C07K14/46 ,  C07K16/18 ,  C07K16/24 ,  C07K16/28 ,  C07K16/46 ,  A61K38/00

CPC classification number: C07K16/18 ,  C07K14/461 ,  C07K16/241 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/2812 ,  C07K16/461 ,  C07K16/465 ,  A61K38/00 ,  C07K2317/24 ,  C07K2317/64 ,  C07K2319/00

Abstract: CDR-grafted antibody heavy and light chains comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions (6, 23) and/or (24, 48) and/or (49, 71) and/or (73, 75) and/or (76) and/or (78) and (88) and/or (91). The CDR-grafted light chains comprise donor residues at at least one of positions (1) and/or (3) and (46) and/or (47) or at at least one of positions (46, 48, 58) and (71). The CDR-grafted antibodies are preferably humanized antibodies, having non human, e.g. rodent, donor and human acceptor frameworks, and may be used for in vivo therapy and diagnosis. A generally applicable protocol is disclosed for obtaining CDR-grafted antibodies.

公开(公告)号：US20240344102A1

公开(公告)日：2024-10-17

申请号：US18431564

申请日：2024-02-02

Applicant: Merus N.V.

Inventor： Cornelis Adriaan DE KRUIF ,  Linda Johanna Aleida Hendriks ,  Ton Logtenberg

IPC: C12P21/00 ,  A61K39/395 ,  A61K39/40 ,  C07K16/12 ,  C07K16/18 ,  C07K16/26 ,  C07K16/28 ,  C07K16/36 ,  C07K16/46 ,  A61K39/00

CPC classification number: C12P21/005 ,  A61K39/395 ,  A61K39/3955 ,  A61K39/40 ,  C07K16/12 ,  C07K16/1278 ,  C07K16/1282 ,  C07K16/18 ,  C07K16/26 ,  C07K16/28 ,  C07K16/2809 ,  C07K16/283 ,  C07K16/2866 ,  C07K16/2896 ,  C07K16/36 ,  C07K16/468 ,  A61K2039/507 ,  C07K2317/14 ,  C07K2317/31 ,  C07K2317/526 ,  C07K2317/56 ,  C07K2317/94

Abstract: The invention provides means and methods for producing one or more Ig-like molecules in a single host cell. Novel CH3 mutations enabling the production of monospecific and/or bispecific Ig-like molecules of interest are also provided.

公开(公告)号：US20240344030A1

公开(公告)日：2024-10-17

申请号：US18292670

申请日：2022-07-28

Applicant: Cartesian Therapeutics, Inc.

Inventor： Yi Zhang ,  C. Andrew Stewart ,  Metin Kurtoglu ,  Sjaji Daniel ,  Murat V. Kalayoglu ,  Minhtran Ngo Casi

IPC: C12N5/0775 ,  C07K14/54 ,  C07K14/715 ,  C07K16/28 ,  C12N15/85

CPC classification number: C12N5/0662 ,  C07K14/5434 ,  C07K14/7158 ,  C07K16/2809 ,  C07K16/2878 ,  C12N15/85 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/92 ,  C12N2800/107

Abstract: Provided here are cells engineered for therapeutic purposes to express multiple proteins, including an anti-BCMA (B cell maturation antigen), anti-CD3 bispecific antibody. Also provided are new anti-BCMA, anti-CD3 bispecific antibodies with associated sequences. Further disclosed is a mesenchymal stem cell (MSC) comprising an exogenous mRNA encoding an anti-BCMA and anti-CD3 antibody, and an exogenous mRNA encoding a single-chain interleukin-12 (IL-12) fusion protein.

公开(公告)号：US20240343827A1

公开(公告)日：2024-10-17

申请号：US18612342

申请日：2024-03-21

Applicant: Gensun Biopharma (MXY)

Inventor： Margaret KAROW ,  Richard Yau ,  Jackie SHENG

IPC: C07K16/30 ,  A61K39/00 ,  A61K45/06 ,  C07K16/28 ,  C07K16/46

CPC classification number: C07K16/3092 ,  A61K45/06 ,  C07K16/2809 ,  C07K16/2878 ,  C07K16/468 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/75

Abstract: Provided are bispecific T Cell Engagers. More specifically, the invention is directed to bispecific molecules that bind to DLL3, MUC17 or CLD18 and activate CD (cluster of differentiation) molecules (e.g. CD3, CD28 and CD137). Also provided are methods of treating an ailment such as cancer using an antibody (or fragment) against DLL3, MUC17 or CLD18 paired with an antibody (or fragment) of an agonist antibody that activates CD3, CD28 and/or CD137.

公开(公告)号：US20240343809A1

公开(公告)日：2024-10-17

申请号：US18580389

申请日：2022-07-19

Applicant: EXCELMAB INC.

Inventor： Wenjun ZHANG ,  Min LIU ,  Wenwu TIAN ,  Feng LI ,  Yanan HUA

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00

CPC classification number: C07K16/2827 ,  A61P35/00 ,  C07K16/2809 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/51 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/56

Abstract: A B7-H3 antibody and a use thereof are provided. The heavy chain complementarity determining regions of the B7-H3 antibody include the amino acid sequences shown in SEQ ID NOs. 6-8, and the light chain complementarity determining regions of the B7-H3 antibody include the amino acid sequences shown in SEQ ID NOs. 14-16. The B7-H3 antibody can bind to a B7-H3 antigen and/or cells expressing the B7-H3 antigen. A B7-H3×CD3 bispecific antibody is constructed by using the B7-H3 antibody.

公开(公告)号：US20240343802A1

公开(公告)日：2024-10-17

申请号：US18612960

申请日：2024-03-21

Applicant: ZYMEWORKS BC INC.

Inventor： Gordon Yiu Kon Ng ,  Surjit Bhimarao Dixit ,  Thomas Spreter von Kreudenstein ,  Nina E. Weisser

IPC: C07K16/28 ,  C07K16/32

CPC classification number: C07K16/2809 ,  C07K16/2803 ,  C07K16/2887 ,  C07K16/32 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/52 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/528 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2317/71 ,  C07K2317/72 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/74 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/31

Abstract: Disclosed herein are isolated multi-specific heteromultimer constructs that bind to CD3 expressed on T-cells and to an antigen expressed on B-cells. The multi-specific heteromultimer constructs are capable of bridging T- and B-cells and mediating killing of B-cells. The multi-specific heteromultimer constructs are based on a heterodimeric Fc scaffold or on a segmented albumin scaffold. Also disclosed herein are multi-specific heteromultimer constructs that bind to HER2 and HER3.

公开(公告)号：US20240336702A1

公开(公告)日：2024-10-10

申请号：US18743295

申请日：2024-06-14

Applicant: AB STUDIO INC.

Inventor： Yue Liu ,  Wenyan Cai ,  Jiadong Shi

IPC: C07K16/46 ,  A61K39/00 ,  A61P35/00 ,  C07K16/28

CPC classification number: C07K16/468 ,  A61P35/00 ,  C07K16/2809 ,  C07K16/2827 ,  C07K16/2896 ,  A61K2039/505

Abstract: This disclosure relates to bispecific antibodies or antigen-binding fragments thereof, wherein the bispecific antibodies or antigen-binding fragments thereof specifically bind to two different antigens with different binding affinities.